A Single Exposure Clinical Trial to Evaluate the Dose Duration Response of Mometasone Furoate Cream and Vasoconstrictive Activity of MK0887G Topically applied to the skin of Healthy Subjects

Merck Sharp and Dohme Corp, a subsidiary of Merck & Co., Inc.0 个研究点目标入组 192 人开始时间: 2012年10月9日最近更新: 2020年1月13日

试验速览

暂无简介。

•BMI between 18-32 kg/m2 inclusive
•-Female of reproductive potential to have negative pregnancy test and agree to use double-barrier contraception
•-Good health based on medical history, physical examination, vital sign measurements, ECG and laboratory assessments
•-Non smoker
•-Demonstrate an adequate vasoconstriction response to commercial mometasone furoate cream (visual score of 1 or greater)
•-Be willing to abide by dietary/exercise restrictions

•-Female who is pregnant or intending to become pregnant within 3 months, or currently breastfeeding
•-History of clinically significant abnormalities or diseases
•-History of cancer (malignancy)
•-History of significant multiple and/or severe allergies or anaphylaxis
•-Infectious disease within 4 weeks
•-History of dermatitis, eczema or psoriasis
•-Positive to Hepatitis B, C or HIV
•-Positive drug screen
•-Has had major surgery, donated or lost 1 unit of blood within 4 weeks
•-Consumes excessive amounts of alcohol
•-Active dermatitis, injuries or markings to the forearms
•-Subjects who would require shaving of the forearms
•-Obvious visual difference in skin color between arms
•-Used concomitant medications within protocol specified intervals for different classes of drug
•-Previous allergic or irritant reaction to topical corticosteroids or components of any topical formulation

发起方

Merck Sharp and Dohme Corp, a subsidiary of Merck & Co., Inc.